Denali Advisors LLC Gilead Sciences, Inc. Transaction History

Denali Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 30, 2020	SELL	$61.62 - $67.78 $10 Million - $11 Million	-162,703 Closed	0 $0
Q3 2019 Oct 09, 2019	SELL	$62.51 - $69.0 $18,753 - $20,700	-300 Reduced 0.18%	162,703 $10.3 Million
Q2 2019 Jul 08, 2019	BUY	$61.87 - $69.38 $1.28 Million - $1.44 Million	20,700 Added 14.55%	163,003 $11 Million
Q1 2019 Apr 12, 2019	SELL	$62.53 - $70.05 $1.14 Million - $1.28 Million	-18,300 Reduced 11.39%	142,303 $9.25 Million
Q3 2018 Oct 09, 2018	BUY	$71.28 - $78.92 $370,656 - $410,384	5,200 Added 3.35%	160,603 $12.4 Million
Q2 2018 Jul 11, 2018	BUY	$64.88 - $75.68 $927,783 - $1.08 Million	14,300 Added 10.13%	155,403 $11 Million
Q1 2018 Apr 23, 2018	SELL	$72.84 - $88.8 $14,568 - $17,760	-200 Reduced 0.14%	141,103 $10.6 Million
Q4 2017 Jan 24, 2018	BUY	$71.15 - $83.52 $122,804 - $144,155	1,726 Added 1.24%	141,303 $10.1 Million
Q3 2017 Oct 19, 2017	BUY	$72.11 - $85.47 $10.1 Million - $11.9 Million	139,577	139,577 $11.3 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Denali Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Denali Advisors LLC with notifications on news.